Skip to content

Clinical research of probiotics on intestinal microecology and prognosis in breast cancer patients undergoing chemotherapy: a prospective randomized controlled trial

Clinical research of probiotics on intestinal microecology and prognosis in breast cancer patients undergoing chemotherapy: a prospective randomized controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037383
Enrollment
Unknown
Registered
2020-08-28
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

control group:chemotherapy
experimental group:Chemotherapy + probiotics

Sponsors

Shanghai Tenth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The patients diagnosed as invasive breast cancer by histopathology and have received breast cancer surgery (including simple mastectomy + sentinel lymph node biopsy, modified radical mastectomy and breast conserving radical mastectomy); 2. Patients who received chemotherapy for the first time after breast cancer surgery and received Tec regimen; 3. The survival time of patients with karnofshy score >= 75 was more than 3 months; 4. The patients had no serious cardiovascular and cerebrovascular diseases, digestive tract diseases or mental diseases, and their blood routine, liver and kidney functions, cardiac functions and electrocardiogram were normal before chemotherapy; 5. Ask for informed consent of patients and volunteer for the test.

Exclusion criteria

Exclusion criteria: 1. Patients with previous history of other malignant tumors; 2. Patients with gastrointestinal diseases such as inflammatory bowel disease, diverticulitis, chronic diarrhea or constipation; 3. Patients with oral antibiotics within one month before chemotherapy, such as penicillins, cephalosporins, aminoglycosides and macrolides.

Design outcomes

Primary

MeasureTime frame
Immune index;

Secondary

MeasureTime frame
Complete Blood Count;Stool routine;Tumor markers;nutritional indicator;

Countries

China

Contacts

Public ContactQian Mingping

Shanghai Tenth People's Hospital

qian_mp@126.com+86 18917681320

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026